Cross-source identity
National Provider Identifier 1558360784 as it appears in every federal dataset Fonteum holds. Each row is a distinct public source; the chip carries the source and the snapshot date behind that field — the record-level form of the source-provenanced graph.
| Federal source | Key | What it provides | Provenance |
|---|
| CMS NPPES | NPI 1558360784 | Registry identity — psychiatrist, taxonomy 2084P0800X | Source:CMS NPPESSnapshot 2026-05-06 |
| CMS Open Payments | NPI 1558360784 | 196 industry-payment records, 2024 | Source:CMS Open PaymentsSnapshot PY2024 |
| CMS Medicare Part D | NPI 1558360784 | 48 drugs prescribed, 2024 | Source:CMS Part DSnapshot DY2024 |
| Fonteum entity graph | entity edfa7c58… | Canonical resolved node · 4 identifier(s) · 6 edge(s) | Source:Entity graphSnapshot 2026-06-11 |
Industry payments
Payments and transfers of value this clinician received from drug and device manufacturers, disclosed under the Physician Payments Sunshine Act. A payment is a disclosure, not a judgment.
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $52,555 | 23 |
| Consulting Fee | $23,588 | 5 |
| Travel and Lodging | $9,508 | 28 |
| Food and Beverage | $3,857 | 139 |
| Honoraria |
| Manufacturer | Amount | Records |
|---|---|---|
| Alkermes, Inc. | $23,621 | 44 |
| Axsome Therapeutics, Inc. | $18,596 | 22 |
| Teva Pharmaceuticals Usa, Inc. | $15,982 |
Prescribing
Prescriptions written under Medicare Part D, aggregated by drug across the program. Totals reflect claims paid, not patients treated.
| Drug | Claims | Drug cost |
|---|---|---|
| Vraylar(Cariprazine Hcl) | 38 | $54,665 |
| Trintellix(Vortioxetine Hydrobromide) | 18 | $14,661 |
| Vyvanse(Lisdexamfetamine Dimesylate) | 16 | $6,011 |
| Buprenorphine-Naloxone(Buprenorphine Hcl/Naloxone Hcl) | 32 | $5,529 |
| Belsomra(Suvorexant) | 11 | $4,739 |
Beneficiary counts below 11 are suppressed by CMS — the total shown is a lower bound.
Quality
CMS Quality Payment Program Merit-based Incentive Payment System (MIPS) final score, where this clinician participated. Absence of a score is not a quality signal — many clinicians report through a group or are exempt.
Enrollment & sanctions
Screening aid — re-confirm any match against the issuing list before acting. A clean result means no record was found in the federal OIG LEIE or the state Medicaid lists Fonteum currently holds (NY, OH, GA), not a guarantee that none exists elsewhere. Not a legal or credentialing certification.
Ownership & affiliations
One-hop relationships in the resolved entity graph — chain membership, ownership, and operation edges, each backed by a federal source row. Most individual clinicians carry none; edges populate for owners and organizations as the Lane D backfill runs.
| Relationship | Entity | Source |
|---|---|---|
| ← pays | Janssen Pharmaceuticals, Inc (NJ) | cms_open_payments |
| ← pays | Neos Therapeutics, Lp (CO) | cms_open_payments |
| ← pays | Noven Therapeutics, Llc (FL) | cms_open_payments |
| ← pays | E.R. Squibb & Sons, L.L.C. (NJ) | cms_open_payments |
| ← pays | Abbvie Inc. (IL) | cms_open_payments |
| ← pays | Eisai Inc. (NJ) | cms_open_payments |
| 1 |
| 30 |
| Supernus Pharmaceuticals, Inc. | $15,477 | 37 |
| E.R. Squibb & Sons, L.L.C. | $12,413 | 15 |